Stem Cell Derived: 20 Billion 40 Billion 100 Billion MSC Exosomes

The use of regenerative medicine product such as BMA, PRP, Amnio, MSC Exosomes, and Stem Cells has skyrocketed the last decade. While some patients have reported great outcomes others have reported no effectiveness, and in worse cases harm has come in the form of harm through autoimmune responses, viruses, and tumors. But our Dynacord MSC Exosomes are created in a controlled environment achieving consistent composition through various batches and donors. They are rigorously tested through the same batch safety tests as used in the pharmaceutical industry.


An injured tissue releases chemical markers signaling their damage.

Absorb + Create

A stem cell absorbs the markers and creates the components for healing.

3d illustration of X chromosomes
The stem cell packages into a vesicle called an exosomes.
Source of Healing

The MSC Exosome goes to injured tissue and attaches itself.

MSC Exosomes FAQ

Due to the high medical risks of using live stem cells, they have been highly regulated. Currently, the only legal way to use live stem cells is if they are derived from the patient themselves or are not manipulated in any way and used as a tissue transplant. These current methods of using live stem cells have major shortcomings beyond the health risk. First, any tissue that is used as a transplant is limited in its application in only being able to be applied to similar tissue (placenta membranes may only be used on similar skin type tissues). Second, any self derived stem cells are subject to degradation due to aging. At the age of 40 a person’s stem cells begin to lose effectiveness. By the age of 60, the age of most patients needing stem cell treatments, the stem cells are barely effective, if at all.

Dynacord combats this by using a placenta from a new birth and extracting the mesenchymal stem cells. This allows us to use the newest and most potent stem cells possible. They then screen and culture them in a lab to control safety and efficacy of the cells. They then immerse them in the appropriate medium which allows them to secrete exosomes with consistent and high quantities of regenerative factors. Finally we extract the exosomes and analyze them through batch testing at which point they are made available for research purposes.

Compared to stem cells, the exosome treatment is cell free and therefore represents a low-risk treatment compared to stem cells. Studies have shown that treatments with exosomes show similar or better results when compared to stem cell treatment. Based on this information, it is thought that stem cell treatment facilitates its beneficial effects through the secretion of exosomes rather than effects of the stem cells themselves. By using exosomes directly, we can eliminate the injection of stem cells which is known to cause potential issues during treatment.

The team at Dynacord has spent the last 9 years researching the most safe and efficacious way to bring regenerative medicine to market while abiding by Federal regulatory policy. Since that time, we have pursued research into the stem cell field and refined our understanding of the mechanisms at play and evolved our approach to best meet the regulatory standards that have been developed. We established strategic partnerships with LSU Health Foundation and Dr. Lucio Miele, the former senior investigator for the FDA’s Center for Biologics Evaluation and Research (the authority on regenerative medicine regulation). Through guidance and research, we learned that the most efficacious and safe method of treating people with injury is using placental derived mesenchymal stem cell exosomes. We have worked tirelessly since this time self funding our research and working with local medical facilities for placental material used in our research in order to be the frontrunner in the industry and soon become the first fully legal, FDA approved umbilical cord mesenchymal stem cell derived exosome product on the market.


We are pursuing the following future product lines and are looking forward to getting appropriate FDA clearances to allow sales and distribution of these products soon.

for FDA Devices/saline

Case of 20x 5ml eye droppers

Packaging to be determined

Hydro Gel in a medical spray, possibly coupled with a bandage


Dropper bottle with calibrated dropper

Dropper bottle for use with nebulizer

Pressurized inhaler

Squeeze spray bottle for sazal inhalation

Specialized applicator utilizing a Hydro Gel

Articles About MSC Exosomes
The biology, function, and biomedical applications of exosomes
Exosomes are a type of extracellular vesicle that contain constituents (protein, DNA, and RNA) of the cells that secrete them. They are taken up by distant ...

Concise Review: MSC-Derived Exosomes for Cell-Free Therapy
More recently, MSC-derived extracellular vesicles (EVs), which include exosomes and microvesicles (MV), are being examined for their role in MSC-based cellular ...

Videos About Exosomes